BeyondSpring Elevates Min Qiu to CEO and Na Li to CFO for DUBLIN-4
BYSI•BeyondSpring will appoint Min Qiu as CEO, Dr. Jiangwen Majeti as Vice Chairman and Na Li as CFO effective July 1, 2026, to complete its DUBLIN-4 Phase 3 program for Plinabulin in EGFR wild-type NSCLC. Chair Dr. Lan Huang will continue oversight to support global partnerships and IP protection.
1. Leadership Transition and Objectives
Effective July 1, 2026, BeyondSpring will install Min Qiu as Chief Executive Officer, Dr. Jiangwen (Jen) Majeti as Vice Chairman and Na Li as Chief Financial Officer, while founder Dr. Lan Huang remains Chairman. The Board structured these appointments to concentrate operational leadership on completing the DUBLIN-4 trial and expanding global partnerships.
2. Focus on DUBLIN-4 Phase 3 Program
The confirmatory DUBLIN-4 trial tests Plinabulin in EGFR wild-type non-small cell lung cancer patients post-immune checkpoint inhibitor therapy. It builds on DUBLIN-3 data showing Plinabulin plus docetaxel doubled two- and three-year survival rates and cut grade 4 neutropenia from 33% to 5%.
3. Plinabulin Scientific Thesis and IP Runway
Plinabulin is a first-in-class GEF-H1 agonist with patents in over 40 jurisdictions through 2036 and potential U.S. exclusivity until 2041 under Hatch-Waxman extension. New preclinical data demonstrate significantly improved tumor regression when combined with ADCs like T-DXd and Dato-DXd, highlighting its unique mechanism.
